The city of Grand Rapids, Michigan, currently has 37 active clinical trials seeking participants for Lung Cancer research studies.
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Recruiting
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: START Midwest., Grand Rapids, Michigan
Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC